Michael Skynner - 15 Jul 2026 Form 4 Insider Report for BICYCLE THERAPEUTICS PLC (BCYC)

Reporting relationship: CHIEF SCIENTIFIC OFFICER
Issuer ticker: BCYC
Reported as of: 15 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jul 2026, 16:15:09 UTC
Prior SEC filing: 07 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Travis Thompson, Attorney-in-Fact

Key filing fact

Michael Skynner filed Form 4 for BICYCLE THERAPEUTICS PLC (BCYC) on 17 Jul 2026.

Key facts

This page summarizes Michael Skynner's Form 4 filing for BICYCLE THERAPEUTICS PLC (BCYC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jul 2026, 16:15.

Change

Previous filing in this sequence was filed on 07 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001776582 Primary reporting owner

Skynner Michael

Relationship: CHIEF SCIENTIFIC OFFICER
Address: C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, UNITED KINGDOM
Signature: /s/ Travis Thompson, Attorney-in-Fact
Signature date: 17 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCYC transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value
Shares: +60,000
Change %
Price: $0.000000^*
Shares after: 60,000
Date: 15 Jul 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 60,000
Exercise price: $4.21
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on July 15, 2027 and the remaining shares in 36 equal monthly installments thereafter.